Pre-immunotherapy alters stereotactic ablative radiotherapy-induced systemic T cell responses in early-stage NSCLC by Chao Liu, Yanjuan Chen, Xiaohui Li, Zhijie Bai, Meilin Jiang, Dongsheng Sheng, Wenxue Zou, Rui Huang, Qingyu Huang, Fuhao Wang, Jingyang Zhu, Huiru Sun, Bing Liu, Zongcheng Li, Bing Sun

Subjects: Get full text

Integrated bioinformatics and experimental analysis of CHAF1B as a novel biomarker and immunotherapy target in LUAD by Wei Du, Xiao-Wei Wu, Qing-Feng Li, Bing-Yu Zhang, Jing Wu, Ya-Ping Xu, Xue Yi

Subjects: Get full text

Bacillus Calmette-Guerin (BCG) infections following intravesical BCG immunotherapy: a systematic review protocol by Roberta Monardo, Sana Arif, Aparna Rege, Erin Simon, Leila Ledbetter, Arthur W. Baker, Jason Stout, Manuela Carugati

“…Abstract Background Although intravesical Bacillus Calmette-Guerin (BCG) immunotherapy usually exhibits a favorable safety profile, it can lead to the development of BCG infections, both localized and disseminated. …”
Get full text

Acute Interstitial Nephritis in a Patient with Non-Small Cell Lung Cancer under Immunotherapy with Nivolumab by Panagiotis I. Georgianos, Vasilios Vaios, Eleni Leontaridou, Georgia Karayannopoulou, Triantafyllia Koletsa, Athanasios Sioulis, Elias V. Balaskas, Pantelis E. Zebekakis

“…Immune-checkpoint-inhibitors (ICPIs) represent a novel class of immunotherapy against several malignancies. These agents are associated with several “immune-mediated” adverse effects, but the reported renal toxicity of ICPIs is less well defined. …”
Get full text

Balancing CIK Cell Cancer Immunotherapy and PPAR Ligands: One Potential Therapeutic Application for CNS Malignancies by Kira Vordermark, JingJing Pu, Amit Sharma, Jarek Maciacyzk, Ingo G. H. Schmidt‐Wolf

“…Results Using a clinical applicable PPAR‐γ inhibitor, we showed that (1) PPARγ‐antagonist GW‐9662 suppressed tumor cell growth in both neuroblastoma and glioblastoma cells, (2) PPARγ inhibition had restricted effect on the expression of Wnt/β‐catenin associated genes, (3) inhibition of PPARγ led to downregulation of DNMT1 expression, supporting their hypothesized interaction in cancer, (4) a partial modulation of global LINE‐1 methylation levels was observed, indicating their role in epigenetic processes, and (5) Combining PPARγ inhibition with CIK cell immunotherapy enhanced cell lysis significantly. Conclusion We provide evidence that PPAR ligands in combination with CIK cell immunotherapy could be a valuable option for malignant CNS tumors.…”
Get full text

Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis by Peijun Tang, Xingnian Chen, Junchi Xu, Yunlong Hu, Zhijian Ye, Xiafang Wang, Yumei Xiao, Xinghua Shen, Jianping Zhang, Yanjun Feng, Cuilin Shi, Xin Yu, Lixian Yi, Xinchun Chen, Binfeng Lu, Ping Xu, Zhongwen Sun, Meiying Wu

“…However, the efficacy of CIK immunotherapy in the treatment of MDR-TB infection has not been evaluated in clinical trials. …”
Get full text

Targeting Caveolin‐1 in Multiple Myeloma Cells Enhances Chemotherapy and Natural Killer Cell‐Mediated Immunotherapy by Dewen Zhan, Zhimin Du, Shang Zhang, Juanru Huang, Jian Zhang, Hui Zhang, Zhongrui Liu, Eline Menu, Jinheng Wang

Subjects: Get full text

Clinical characteristics and immunotherapy response in paraneoplastic neurologic syndrome patients with increased number of high-risk antibodies by Gong Wang, Mao Chen, Fei Gao, Meng Guo, Maohua Li, Qian He, Jiaojin Jiang, Cheng Huang, Xiaoyan Chen, Rui Xu

Subjects: Get full text

Pan-cancer analysis and single-cell analysis identifies the CENPN as a biomarker for survival prognosis and immunotherapy by Nie Zhang, Zhuoying He, Xuejin Qin, Ke Han, Zhengchun Zhu, Fei Zhong

Get full text

Case report: Innovative approach to esophageal cancer with right aortic arch: neoadjuvant immunotherapy and 3D reconstruction by Chengwen Luo, Zhilin Luo

Subjects: Get full text

Immunotherapy and Antivascular Targeted Therapy in Patients’ Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge by Bairu Shen, Zi Guo, Peng Huang, Minghua Tan, Xiaoshen Zhang, Siyao Lin, Changshan Song, Jiaqing Wang, Minqian Huang

“…To analyze the therapeutic effects and organ rejection of anti-PD-1 immunotherapy or antivascular targeting therapy on patients with combined malignancies after organ transplantation. …”
Get full text

Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy by Jie Yang, Jian-Guo Zhou, Benjamin Frey, Hu Ma, Haitao Wang, Markus Hecht, Rainer Fietkau, Udo Gaipl, Xiaofei Chen, Ada Hang-Heng Wong, Fangya Tan, Si-Si He, Gang Shen, Yun-Jia Wang, Wenzhao Zhong

“…In addition, the absolute difference in median survival between the SVM-predicted FP and non-FP groups was significant in both progression-free survival and overall survival (p<0.001).Conclusion SVM trained using a 4-biomarker panel has good performance in predicting the occurrence of FP regardless of programmed cell death ligand 1 expression, hence providing evidence for decision-making in single-agent atezolizumab immunotherapy for patients with advanced NSCLC.…”
Get full text

Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report by Zhuren Ruan, Chen Zhao, Longshan Li, Xianghui Li, Zhijian Yao, Gao Wei

Subjects: Get full text

Neoadjuvant Immunotherapy and De-escalation of Surgery in Locally Advanced Breast Implant-associated Anaplastic Large Cell Lymphoma by Marzia Salgarello, Jaroslaw Krupa, Rebecca Allchin, Simon Pilgrim, Fiona Miall, Arianna Di Napoli, Maurizio Martelli, Giulio Tarantino

“…The first case was a 52-year-old patient with a left breast mass-like stage III disease who underwent combined targeted immunotherapy and chemotherapy (brentuximab vedotin [BV]–cyclophosphamide, doxorubicin, prednisone [CHP]). …”
Get full text

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy by Anna De Lucia, Lucia Mazzotti, Lucia Mazzotti, Anna Gaimari, Anna Gaimari, Matteo Zurlo, Roberta Maltoni, Claudio Cerchione, Sara Bravaccini, Angelo Delmonte, Lucio Crinò, Patricia Borges de Souza, Luigi Pasini, Fabio Nicolini, Fabrizio Bianchi, Manel Juan, Hugo Calderon, Chiara Magnoni, Chiara Magnoni, Luca Gazzola, Luca Gazzola, Paola Ulivi, Massimiliano Mazza

“…In this review, we discuss how the understanding of this intricate relationship is crucial for the success of immunotherapy and survey the current state of immunotherapy intervention, with a focus on forthcoming and promising chimeric antigen receptor (CAR) T cell therapies in NSCLC. …”
Get full text

Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing by Ignacio I Wistuba, Michael T Tetzlaff, Carlo B Bifulco, Benjamin Green, Sacha Gnjatic, Scott J Rodig, Joel C Sunshine, Janis M Taube, Keith E Steele, Marlon C Rebelatto, David L Rimm, Ana Lako, Edwin R Parra, Guray Akturk, Michael Angelo, Shirley Greenbaum, Noah F Greenwald, Cyrus V Hedvat, Travis J Hollmann, Kurt A Schalper, Cláudia S Ferreira, Konstanty Korski, Emanuel Schenck, Michael J Surace, Jennifer H Yearley, Jeffrey S Roskes, Margaret Eminizer, Logan L Engle, Daniel Jiménez-Sánchez, Jamie Rodriguez-Canales, Alexander S Szalay

“…Journal for ImmunoTherapy of Cancer…”
Get full text

Contribution of m5C RNA Modification-Related Genes to Prognosis and Immunotherapy Prediction in Patients with Ovarian Cancer by Yibin Liu, Shouze Liu, Lu Yan, Qianqian Zhang, Wenhua Liu, Xianghua Huang, Shikai Liu

“…Our study bridged the gap between m5C RNA modification and the prognosis of OC and was expected to provide an effective breakthrough for immunotherapy in OC patients.…”
Get full text

Corrigendum: Physical parameters and biological factors affect the abscopal effect of combining radiotherapy with immunotherapy: an update on preclinical works by Wangcai Ren, Jialing Wen, Gang Guo, Gang Guo, Wenchao Gu, Shenke Zhang, Shenke Zhang, Chang Liu, Chang Liu, Kensuke Osada, Takashi Shimokawa, Qiaojuan Wang, Qiaojuan Wang, Yue Wang, Yue Wang, Xuanzhang Tu, Chen Li, Li Sui, Liqiu Ma, Liqiu Ma, Liqiu Ma

Get full text

Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II by Zhi-Bin Wang, Zhi-Bin Wang, Zhi-Bin Wang, De-Hua Liao, Guang Lei, Zhao-Qian Liu, Zhao-Qian Liu, Nayiyuan Wu, Nayiyuan Wu, Jing Wang, Jing Wang

Get full text

Intrinsic PD‐L1 Degradation Induced by a Novel Self‐Assembling Hexapeptide for Enhanced Cancer Immunotherapy by Hongxia Zhang, Ming Ji, Yamei Wang, Mengmeng Jiang, Zongyu Lv, Gongyu Li, Lulu Wang, Zhen Zheng

Get full text